Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
GLP‐1 and metabolic syndrome.Bench to bedside.
Kevin Niswender MD, PhDVanderbilt University School of MedicineVanderbilt University School of Medicine
The incretin effect.Control Subjects
(n=8)
L
0.6
0.5
80
60
Incretin Effect
sulin
, mU
/L nmol / L
0.4
0.3
60
40
IR In
s
L
0.2
0.120
Oral glucose load Time min
00
18060 1200g
Intravenous (IV) glucose infusionTime, min
Adapted with permission from Nauck M et al. Diabetologia. 1986;29:46–52. Copyright © 1986 Springer-Verlag.
The Incretin Axis
Hormonal signals• GLP-1• GIP
Glucagon(GLP-1)
alpha alpha cellscellsbbeta cellseta cells
Pancreas
Neural signals
GutInsulin
(GLP-1,GIP)Nutrient signals
Adapted with permission from Creutzfeldt W. Diabetologia. 1979;16:75–85. Copyright © 1979 Springer-Verlag.Drucker DJ. Diabetes Care. 2003;26:2929–2940.Kieffer T et al. Endocr Rev. 1999;20:876–913.Nauck MA et al. Diabetologia. 1993;36:741–744.
Adiposity Negative Feedback SignalingAdiposity Negative Feedback Signalingi.e. regulation of “metabolic drive”
Schwartz MW et al., Nature 2000
Does GLP-1 work in a similar way?Does GLP-1 work in a similar way?
GLP-1 given ICV lowers food intake..GLP 1 given ICV lowers food intake..
Turton et al., Nature 1996
and blunts NPY induced feeding…and blunts NPY induced feeding.
Turton et al., Nature 1996
Reward CircuitryReward Circuitry
Cami NEJM 2003
GLP-1 analogue decreases candy and increases chow intake.(and decreases weight gain)
Raun et al., Diabetes 2007
GLP-1 as an adiposity signal?GLP 1 as an adiposity signal?
• GLP-1 can act in hypothalamic areas toGLP 1 can act in hypothalamic areas to control feeding.
• In rodent models this is not required for• In rodent models, this is not required for an effect on feeding and weight gain.GLP 1 i t d d i ti t f t• GLP-1 is not produced in proportion to fat mass.
• Rather, energy in the form of food stimulates GLP-1 production.
Feeding occurs in meals: ti ti d l t i tisatiation and meal termination.
Schwartz MW et al., Nature 2000
CCK reduces meal sizeCCK reduces meal size
Geary Phys. Beh. 2004
GLP-1 induces satiety and reduces meal size
4*
(MJ)
4
take
(
2
rgy
int
saline GLP-10en
er
Flint et al., JCI 1990
GLP-1 works in periphery as aGLP 1 works in periphery as a satiety factor.
Williams et al., Endocrinology 2008
Energy homeostasis and GLP-1:potential sites/mechanisms of actionpotential sites/mechanisms of action
GLP-1
GLP-1
GLP-1
GLP-1
Schwartz MW et al., Nature 2000
GLP‐1 and GIP Are Degraded by DPP‐4
Meal
Intestinal GIP and GLP-1 release
DPP-4Enzymerelease Enzyme
GIP-(1–42) GIP-(3–42)( )GLP-1(7–36)
Intact
( )GLP-1(9–36)Metabolites
Rapid Inactivation
Half-life*GLP-1 ~ 2 minutes
GIP and GLP-1 Actions
GLP-1 2 minutesGIP ~ 5 minutes
Deacon CF et al. Diabetes. 1995;44:1126–1131.*Meier JJ et al. Diabetes. 2004;53:654–662.
Therapeutic approaches: exenatide and liraglutide.
GLP-1 (amidated form)HisAlaGluGlyThrPheThrSerAspValSerSerTyrLeuGluGlyGlnAlaAlaLysGluPheIleAlaTrpLeuValLysGlyArg amide
Proteolytic inactivation (DPP-4)
7 10 15 20 25 30 35 36
GLP 1 (amidated form)
HisGlyGluGlyThrPheThrSerAspLeuSerLysGlnMetGluGluGluAlaValArgLeuPheIle GluTrpLeuLysAsnGlyGlyProSerSerGlyAlaProProProSeramide
Exenatide
HisAlaGluGlyThrPheThrSerAspValSerSerTyrLeuGluGlyGlnAlaAlaLysGluPheIle AlaTrpLeuVal ArgGlyArgGly
Liraglutide
Glu
C-16 free fatty acidAlbumin
Does the promise translate: glucose?Does the promise translate: glucose?0
Liraglutide Exenatide
0 5(%)
LiraglutideBaseline 8·2%
ExenatideBaseline 8·1%
–0·5
ge in
HbA
1C(
–1·0Chan
g
–1·5
p<0·0001
Buse et al., Lancet 2009
Does the promise translate: weight?Does the promise translate: weight?98 Liraglutide
Exenatide
(kg) 94
96
odyw
eigh
t
90
92
Bo
88
90
086
2 4 6 8 10 12 14Time (weeks)
16 18 20 22 24 26
Buse et al., Lancet 2009
Liraglutide (Victoza) and obesity
Astrup, Lancet 2009
Does the promise translate: Lipids?Liraglutide Exenatide Estimated treatment
difference(liraglutide–exenatide)(95% CI)
p value
Islet function
Fasting insulin (pmol/L) 12·43 (6·93) –1·38 (6·92) 13·81 (0·94 to 26·68) 0·0355
Fasting C-peptide (nmol/L) 0·05 (0·05) –0·02 (0·05) 0·07 (–0·02 to 0·16) 0·1340
Fasting proinsulin-to-insulinratio
0·00 (0·03) –0·02 (0·03) 0·02 (–0·03 to 0·08) 0·4309
HOMA-B 32·12% (6·75%) 2·74% (6·75%) 29·37% (16·81% to <0·000141·93%)
Fasting glucagon (ng/L) –19·44(5·18) –12·33 (5·12) –7·12 (–16·66 to 2·43) 0·1436
Blood pressure
Systolic blood pressure(mm Hg)
–2·51 (1·15) –2·00 (1·18) –0·51 (–2·66 to 1·64) 0·6409
Diastolic blood pressure(mm Hg)
–1·05 (0·71) –1·98 (0·71) 0·93 (–0·37 to 2·23) 0·1610
Lipid profiles
Total cholesterol (mmol/L) –0·20 (0·07) –0·09 (0·07) –0·11 (–0·23 to 0·02) 0·0946
LDL cholesterol (mmol/L) –0·44 (0·06) –0·40 (0·06) –0·04 (–0·15 to 0·06) 0·4412
VLDL cholesterol (mmol/L) 0·20 (0·04) 0·27 (0·04) –0·07 (–0·13 to –0·01) 0·0277
HDL cholesterol (mmol/L) –0·04 (0·02) –0·05 (0·02) 0·01 (–0·02 to 0·04) 0·5105
Triglycerides (mmol/L) –0·41 (0·10) –0·23 (0·10) –0·18 (–0·37 to 0·00) 0·0485
Free fatty acids (mmol/L) –0·17 (0·02) –0·10 (0·02) –0·07 (–0·11 to –0·03) 0·0014
Apolipoprotein B (g/L) –0·06 (0·02) –0·03 (0·02) –0·02 (–0·05 to 0·01) 0·1119Apolipoprotein B (g/L) 0 06 (0 02) 0 03 (0 02) 0 02 ( 0 05 to 0 01) 0 1119
Data are least square means (SE). HOMA-B=homoeostasis model assessmentβ-cell function. LDL=low-densitylipoprotein. HDL=high-density lipoprotein.VLDL=very low-density lipoprotein.
Change in indicesof islet function and cardiovascular risk from baseline to week 26Buse et al., Lancet 2009
Does the promise translate: exenatide 82 weeks?
234
Quartile I II III IV
Systolic BP
Quartile I II III IV
Diastolic BP
Hg) 2
34
mH
g)
–3–2–1
01
ysto
lic B
P (m
m
–3–2–1
01
ΔD
iast
olic
BP
(mm
–6–5–4
ΔS
–6–5–4Δ
Triglycerides HDL C
Quartile I II III IV Quartile I II III IV
–20
0
Triglycerides
/dl)
789
HDL-C
–80
–60
–40
Trig
lyce
ride
(mg/
234567
ΔH
DL
(mg/
dl)
–120
–100Δ
012
Blonde, DOM 2006